Viridian Therapeutics, Inc.\DE (VRDN) Revenue (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Revenue of $141000.0 for Q1 2026, up 95.83% year-over-year from $72000.0 in Q1 2025, and up 6.82% quarter-over-quarter from $132000.0 in Q4 2025.
Powered by 
Analysis
Viridian Therapeutics, Inc.\DE (VRDN) Revenue (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Revenue history runs 14 years deep, the most recent figure standing at $141000.0 for Q1 2026.
- In Q1 2026, Revenue rose 95.83% year-over-year to $141000.0; the TTM figure through Mar 2026 stood at $70.9 million (up 23382.78% YoY), while the FY2025 annual figure was $70.8 million, up 23359.93% from the prior year.
- Revenue for Q1 2026 stood at $141000.0, up from $132000.0 in the prior quarter.
- The five-year high for Revenue was $70.6 million in Q3 2025, with the low at $72000.0 in Q2 2023.
- The 5-year median for Revenue is $86000.0 (2024), against an average of $4.3 million.
- The sharpest annual moves came in 2023 and 2025: Revenue sank 93.97% in 2023, then surged 81958.14% in 2025.
- Viridian Therapeutics, Inc.\DE's Revenue stood at $105000.0 in 2022, then plunged by 31.43% to $72000.0 in 2023, then changed by 0.0% to $72000.0 in 2024, then surged by 83.33% to $132000.0 in 2025, then grew by 6.82% to $141000.0 in 2026.
- Business Quant data shows VRDN's Revenue at $141000.0 in Q1 2026, $132000.0 in Q4 2025, and $70.6 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 145.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.71 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 674.14 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.42 Bn | 2.42 Bn | - | 284,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 284,000.00 |
| Mar 31, 2026 | 141,000.00 |
| Dec 31, 2025 | 132,000.00 |
| Sep 30, 2025 | 70.57 Mn |
| Jun 30, 2025 | 75,000.00 |
| Mar 31, 2025 | 72,000.00 |
| Dec 31, 2024 | 72,000.00 |
| Sep 30, 2024 | 86,000.00 |
| Jun 30, 2024 | 72,000.00 |
| Mar 31, 2024 | 72,000.00 |
| Dec 31, 2023 | 72,000.00 |
| Sep 30, 2023 | 72,000.00 |
| Jun 30, 2023 | 72,000.00 |
| Mar 31, 2023 | 98,000.00 |
| Dec 31, 2022 | 105,000.00 |
| Sep 30, 2022 | 1.20 Mn |
| Jun 30, 2022 | 256,000.00 |
| Mar 31, 2022 | 216,000.00 |
| Dec 31, 2021 | 214,000.00 |
| Sep 30, 2021 | 208,000.00 |